Pharmacoeconomic approaches for pharmacotherapy of rheumatoid arthritis

I. G.  Hayduchok; V. O.  Shapovalova; K. E.  Ishcheikin; V. V.  Chopyak; V. V.  Shapovalov (Jr.); V. V.  Shapovalov

doi:10.31640/JVD.1-2.2021(11)

I. G. Hayduchok Lviv Medical Institute LLC
V. O. Shapovalova Kharkiv Medical Academy of Postgraduate Education
K. E. Ishcheikin State Institution «Kundiiev Institute of Occupational Health of the National Academy of Medical Sciences of Ukraine»
V. V. Chopyak Danylo Halytsky Lviv National Medical University
V. V. Shapovalov (Jr.) Kharkiv Medical Academy of Postgraduate Education, Advocates company «Apotheosis»
V. V. Shapovalov Lviv Medical Institute LLC, Ukrainian National Bar Association

DOI: https://doi.org/10.31640/JVD.1-2.2021(11)

Keywords: pharmacotherapy; systemic autoimmune diseases; rheumatoid arthritis; drugs’ INN; pharmacoeconomic; ABC/VEN analysis.

Abstract

Introduction. With the spread of the coronavirus pandemic, the role of pharmacotherapy of rheumatoid arthritis (RA) among patients with dual health disorders and in patients with systemic diseases is growing. This article is devoted to pharmacoeconomic for the pharmacotherapy of RA based on ABC/VEN analysis. Materials and methods. International and national medical and technological documents on standardization of medical care of RA, as well as scientific sources were used for regulatory, documentary and pharmacoeconomic analysis. ABC analysis was performed as a tool to study the cost of purchasing drugs. VEN analysis was performed to classify drugs into categories V, E and N on the principles of evidence-based medicine, forensic pharmacy, evidence-based pharmacy. Results. On the first stage of the research was conducted clinical and pharmacological analysis, the next stages - marketing and pharmacoeconomic analysis. Based on the ABC/VEN analysis, a matrix of the consolidated ABC/VEN analysis was developed. Discussion. The largest share (66.7 %) falls on the ATC classification code L "Antineoplastic and immunomodulatory agents". According to the results of marketing analysis tablets occupy 50 % of doctors' appointments; 75 % of the studied drugs have an unlimited validity of registration certificates. Ranking of country of origin of manufacturers of studied drugs: Germany – 37.6 %. Category A included five drugs’ INN (Mycophenolic acid, Azathioprine, Cyclophosphamide, Methotrexate, Ciclosporine), the cost of one dose is 5241.1 UAH, which is 78.12 % of the total cost of treatment for a patient with RA. It was found that six drugs INN (Methotrexate, Sulfasalazine, Hydroxychloroquine, Azathioprine, Ciclosporine, Cyclophosphamide) belong to category V (Vital). Conclusion. The introduction of information about pharmacoeconomic for pharmacotherapy of RA in the activities of health care institutions will ensure proper organization of the order of drug circulation at the stages of prescribing, prescribing, storage, accounting, quality control, transportation, release, destruction, licensing in accordance with current medical and pharmaceutical legislation.

Downloads

Download data is not yet available.

References

Gajduchok І. G., Shapovalova V. O., Shapovalov V. V., Shapovalov V. V. Rezhim kontrolyu lіkars'kih zasobіv dlya farmakoterapії revmatoїdnogo artritu. Іnformacіjnij list pro novovvedennya Ukrmedpatentіnform MOZ Ukraїni. – Kiїv: Ukrmedpatentіnform MOZ Ukraїni. – 2021. – № 36. – 2021. – 7 p.

Gajduchok І. G., Shapovalova V. O., Shapovalov V. V., Shapovalov V. V. Rezhim kontrolyu antibakterіal'nih lіkars'kih zasobіv dlya farmakoterapії koronavіrusnoї hvorobi (COVID-19) u pacієntіv z dual'nimi rozladami. Іnformacіjnij list pro novovvedennya Ukrmedpatentіnform MOZ Ukraїni. – Kiїv: Ukrmedpatentіnform MOZ Ukraїni. – 2020. – № 230. –2020. – 6 p.

Gajduchok І. G., Shapovalova V. O., Shapovalov V. V., Shapovalov V. V. Rezhim kontrolyu lіkars'kih zasobіv dlya farmakoterapії koronavіrusnoї hvorobi (COVID-19) u hvorih na sistemnі zahvoryuvannya. Іnformacіjnij list pro novovvedennya Ukrmedpatentіnform MOZ Ukraїni. – Kiїv: Ukrmedpatentіnform MOZ Ukraїni. – 2020. – № 225. – 2020. – 6 p.

Єmchenko Ya. O., Іshchejkіn K. Є., Kajdashev І. P. Analіz zahvoryuvanostі ta poshirenostі na psorіaz v Ukraїnі ta v Poltavs'kіj oblastі // Vіsn. VDNZU «Ukr. med. stomat. akademіya». – 2014. – T. 14, Vip. 3. – P. 72–76.

Abbud Aymen. Comparative analysis of comorbid conditions in patients with psoriasis, taking into account the sex of the subjects // Dermatovenereology. Cosmetology. Sexopathology. – 2015. – N. 1–2. – P. 90–92

Akira Hashimoto , Motoki Sonohata , Masaaki Mawatari . The Use of Oral Analgesics and Pain Self-Efficacy Are Independent Predictors of the Quality of Life of Individuals with Rheumatoid Arthritis // Pain. Res. Manag. – 2020. – https://www.pubmed.ncbi.nlm.nih.gov/32774569. – DOI: 10.1155/2020/7409396

ATC-classification. Compendium on-line. – http://www.compendium.com.ua/atc

Davis J. M., III Eric L., Matteson My. – Treatment Approach to Rheumatoid Arthritis // Mayo. Clin. Proc. – 2012. – Vol. 87, N. 7. – Р. 659–673. – DOI: 10.1016/j.mayocp.2012.03.011. – https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538478

Five Types of Medication That Treat Rheumatoid Arthritis // Veritas health. – 2021 January 24. – https://www.arthritis-health.com/types/rheumatoid/5-types-medication-treat-rheumatoid-arthritis-ra

Glen S., Barnabe C., Tomlinson G. et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis // BMJ. – 2016 April 21. – DOI: 10.1136/bmj. i1777. – https://www.pubmed.ncbi.nlm.nih.gov/27102806

Koop M. W., Klooster P. M., Vonkeman H. E. et al. Rheumatoid Arthritis Medication List. – Healthline, 2016 Jule 08. – https://www.healthline.com/health/rheumatoid-arthritis/medications-list

Mamarde A. ABC/VEN Analysis of drug store in Tertiary care hospital for year 2013–2014 // Am. J. of Pharmaceutical Research. – 2016. – Vol. 6, N. 8. – P. 6439–6444.

Management Science for Health. – Managing Medicines Selection. – Managing Access to Medicines and Health Technologies. – USA: Arlington, 2012. – P. 16.1–16.15.

Ministry of healthcare of Ukraine official site. – http://www.moz.gov.ua

National list of basic medicines. – Resolution of the Cabinet of Ministers of Ukraine. – 2009 March 25. – N. 333. – http://www.zakon4.rada.gov.ua

Neuropathic-like pain features and cross-sectional associations in rheumatoid arthritis // Arthritis Res. Ther. – 2015. – Vol. 17, N. 1. – Р. 237. – DOI: 10.1186/s13075-015-0761-8

On approval of the twelfth issue of the State formulary of medicines and ensuring its availability. – Order of the Ministry of Health of Ukraine. – 2020 May 06. – N. 1075. – http://www.zakon4.rada.gov.ua

On approval and implementation of medical and technological documents for the standardization of medical care for Rheumatoid Arthritis. – Order of the Ministry of Health of Ukraine. – 2014 April 11. – N. 263. – http://www.zakon4.rada.gov.ua

Parnes O. Autoimmune disease // The Lancet. – 2018. – N. 367. – P. 389.

Rheumatoid Arthritis. – EBM Guidelines 00456. – Latest change 2016 October 31, Kari Puolakka. – Duodecim Medical Publications Ltd. 2018. http:/www./guidelines.moz.gov.ua/documents/967

Shapovalov (Jr.) V., Gudzenko A., Komar L. et al. Concerning the importance of forensic and pharmaceutical researches to improve patients’ accessibility to medicines // Pharmacia. – 2017. – Vol. 65, N. 2. – P. 23–29.

Shapovalov (Jr.) V., Gudzenko A., Shapovalov V., Shapovalova V. Organizational and legal aspects of the use of pharmacoeconomic analysis of multivitamin complexes for pharmaceutical provision of military personnel // The Pharma Innovation J. – 2018. – Vol. 7, N. 10. – P. 166–169.

Shapovalov (Jr.) V., Gudzenko A., Shapovalova V. et al. Forensic and pharmaceutical study of the presence of a causal link between the degree of alcohol abuse and qualification level of the respondents // Pharmacia. – 2017. – Vol. 66, N. 3. – P. 31–39.

Shapovalov (Jr.) V, Zbrozhek S., Gudzenko A. et al. Organizational and legal analysis of the pharmaceutical provision for the most common diseases of society // International Journal of Pharmaceutical Sciences Review and Research. – 2018. – Vol. 51, N. 18. – P. 118–124.

Shapovalova V. O., Zbrozhek S. I., Shapоvalov (Jr.) V. V., Shapovalov V. V. Coronavirus disease pandemia 2019: growth of epidemic dangers // Acta scientific pharmaceutical sciences. – 2020 June 02. – Published: 2020 July 01. – Vol. 4, N. 7. – P. 61–68.

Shapovalova V. A., Zbrozhek S. I., Shapovalov V. V, Shapovalov V. V. Forensic pharmacy: some risk factors in the formation of addictive health disorders // Acta Scientific Pharmaceutical Science. – 2021. – Vol. 4, N. 1. – P. 7–12. – DOI: 10.3180 / ASPS.2020.05.0651

Shikang Meng, Zibei Lin, Yan Wang, Zhenping Wang et al. Psoriasis therapy by Chinese medicine and modern agents // Chin. Med. – 2018. – N. 13. – 16 р. – DOI: 10.1186/s13020-018-0174-0

Takakubo K., Konttinen Y. Immune-regulatory mechanisms in systemic autoimmune and rheumatic diseases // Clin. Dev. Immunol. – 2012. – Vol. 37, N. 3. – P. 341–346.

Wilsdon T. D., Hill C. L. Managing the drug treatment of rheumatoid arthritis // Aust. Prescr. – 2017. – Vol. 40, N. 2. – Р. 51–58. – https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408004 – DOI: 10.18773/austprescr.2017.012